Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (23223)	7/15/1998 8:20:00 AM
From: Biotech Jim	Read Replies (2) \| Respond to of 32384

A targeted approach with combichem is now relatively straightforward to pursue with the G-CSF lead. In fact it may be result in a targetted approach for other small molecule mimics of cytokine receptors. Note the pseudosymmetry of SB 247464 and ask any chemist involved in analoging such compounds. There will be a plethora of labs making and testing similar compounds. My concern is that LGND went ahead and published the work that will ultimately enable many others. Until a compound is approved as a result of clinical trials there can be many issues that come up that kill the compound or series. Nonetheless this is a great scientific advance.